6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
described O
in O
more O
detail O
in O
other O
sections O
of O
the O
prescribing O
information O
. O

* O
Myelosuppression B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Infection B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Electrocardiographic B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
were O
neutropenia O
, O
lymphopenia O
, O
thrombocytopenia O
, O
infections O
, O
nausea O
, O
fatigue O
, O
vomiting O
, O
anorexia O
, O
anemia O
, O
and O
ECG O
T-wave O
changes O
( O
6 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Celgene O
Corporation O
at O
1-888-423-5436 O
or O
the O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Cutaneous B-Not_AE_Candidate
T I-Not_AE_Candidate
- I-Not_AE_Candidate
Cell I-Not_AE_Candidate
Lymphoma I-Not_AE_Candidate
The O
safety O
of O
ISTODAX O
was O
evaluated O
in O
185 O
patients O
with O
CTCL B-Not_AE_Candidate
in O
2 O
single O
arm O
clinical O
studies O
in O
which O
patients O
received O
a O
starting O
dose O
of O
14 O
mg/m O
2 O
. O

The O
mean O
duration O
of O
treatment O
in O
these O
studies O
was O
5.6 O
months O
( O
range O
: O
< O
1 O
to O
83.4 O
months O
) O
. O

Common O
Adverse O
Reactions O
Table O
1 O
summarizes O
the O
most O
frequent O
adverse O
reactions O
( O
> O
20 O
% O
) O
regardless O
of O
causality O
using O
the O
National O
Cancer O
Institute-Common O
Terminology O
Criteria O
for O
Adverse O
Events O
( O
NCI-CTCAE O
, O
Version O
3.0 O
) O
. O

Due O
to O
methodological O
differences O
between O
the O
studies O
, O
the O
AE O
data O
are O
presented O
separately O
for O
Study O
1 O
and O
Study O
2 O
. O

Adverse O
reactions O
are O
ranked O
by O
their O
incidence O
in O
Study O
1 O
. O

Laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
commonly O
reported O
( O
> O
20 O
% O
) O
as O
adverse O
reactions O
are O
included O
in O
Table O
1 O
. O

Table O
1 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
20 O
% O
of O
Patients O
in O
Either O
CTCL O
Study O
( O
N=185 O
) O
Adverse O
Reactions O
n O
( O
% O
) O
Study O
1 O
( O
n=102 O
) O
Study O
2 O
( O
n=83 O
) O
All O
grades O
Grade O
3 O
or O
4 O
All O
grades O
Grade O
3 O
or O
4 O
Any O
adverse O
reaction O
99 O
( O
97 O
) O
36 O
( O
35 O
) O
83 O
( O
100 O
) O
68 O
( O
82 O
) O
Nausea B-OSE_Labeled_AE
57 O
( O
56 O
) O
3 O
( O
3 O
) O
71 O
( O
86 O
) O
5 O
( O
6 O
) O
Asthenia B-OSE_Labeled_AE
/ O
Fatigue B-OSE_Labeled_AE
54 O
( O
53 O
) O
8 O
( O
8 O
) O
64 O
( O
77 O
) O
12 O
( O
14 O
) O
Infections B-OSE_Labeled_AE
47 O
( O
46 O
) O
11 O
( O
11 O
) O
45 O
( O
54 O
) O
27 O
( O
33 O
) O
Vomiting B-OSE_Labeled_AE
35 O
( O
34 O
) O
1 O
( O
< O
1 O
) O
43 O
( O
52 O
) O
8 O
( O
10 O
) O
Anorexia B-OSE_Labeled_AE
23 O
( O
23 O
) O
1 O
( O
< O
1 O
) O
45 O
( O
54 O
) O
3 O
( O
4 O
) O
Hypomagnesemia B-OSE_Labeled_AE
22 O
( O
22 O
) O
1 O
( O
< O
1 O
) O
23 O
( O
28 O
) O
0 O
Diarrhea B-OSE_Labeled_AE
20 O
( O
20 O
) O
1 O
( O
< O
1 O
) O
22 O
( O
27 O
) O
1 O
( O
1 O
) O
Pyrexia B-OSE_Labeled_AE
20 O
( O
20 O
) O
4 O
( O
4 O
) O
19 O
( O
23 O
) O
1 O
( O
1 O
) O
Anemia B-OSE_Labeled_AE
19 O
( O
19 O
) O
3 O
( O
3 O
) O
60 O
( O
72 O
) O
13 O
( O
16 O
) O
Thrombocytopenia B-OSE_Labeled_AE
17 O
( O
17 O
) O
0 O
54 O
( O
65 O
) O
12 O
( O
14 O
) O
Dysgeusia B-OSE_Labeled_AE
15 O
( O
15 O
) O
0 O
33 O
( O
40 O
) O
0 O
Constipation B-OSE_Labeled_AE
12 O
( O
12 O
) O
2 O
( O
2 O
) O
32 O
( O
39 O
) O
1 O
( O
1 O
) O
Neutropenia B-OSE_Labeled_AE
11 O
( O
11 O
) O
4 O
( O
4 O
) O
47 O
( O
57 O
) O
22 O
( O
27 O
) O
Hypotension B-OSE_Labeled_AE
7 O
( O
7 O
) O
3 O
( O
3 O
) O
19 O
( O
23 O
) O
3 O
( O
4 O
) O
Pruritus B-OSE_Labeled_AE
7 O
( O
7 O
) O
0 O
26 O
( O
31 O
) O
5 O
( O
6 O
) O
Hypokalemia B-OSE_Labeled_AE
6 O
( O
6 O
) O
0 O
17 O
( O
20 O
) O
2 O
( O
2 O
) O
Dermatitis B-OSE_Labeled_AE
/ O
Exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
4 O
( O
4 O
) O
1 O
( O
< O
1 O
) O
22 O
( O
27 O
) O
7 O
( O
8 O
) O
Hypocalcemia B-OSE_Labeled_AE
4 O
( O
4 O
) O
0 O
43 O
( O
52 O
) O
5 O
( O
6 O
) O
Leukopenia B-OSE_Labeled_AE
4 O
( O
4 O
) O
0 O
38 O
( O
46 O
) O
18 O
( O
22 O
) O
Lymphopenia B-OSE_Labeled_AE
4 O
( O
4 O
) O
0 O
47 O
( O
57 O
) O
31 O
( O
37 O
) O
Alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
3 O
( O
3 O
) O
0 O
18 O
( O
22 O
) O
2 O
( O
2 O
) O
Aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
3 O
( O
3 O
) O
0 O
23 O
( O
28 O
) O
3 O
( O
4 O
) O
Hypoalbuminemia B-OSE_Labeled_AE
3 O
( O
3 O
) O
1 O
( O
< O
1 O
) O
40 O
( O
48 O
) O
3 O
( O
4 O
) O
Electrocardiogram B-OSE_Labeled_AE
ST I-OSE_Labeled_AE
- I-OSE_Labeled_AE
T I-OSE_Labeled_AE
wave I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
2 O
( O
2 O
) O
0 O
52 O
( O
63 O
) O
0 O
Hyperglycemia B-OSE_Labeled_AE
2 O
( O
2 O
) O
2 O
( O
2 O
) O
42 O
( O
51 O
) O
1 O
( O
1 O
) O
Hyponatremia B-OSE_Labeled_AE
1 O
( O
< O
1 O
) O
1 O
( O
< O
1 O
) O
17 O
( O
20 O
) O
2 O
( O
2 O
) O
Hypermagnesemia B-OSE_Labeled_AE
0 O
0 O
22 O
( O
27 O
) O
7 O
( O
8 O
) O
Hypophosphatemia B-OSE_Labeled_AE
0 O
0 O
22 O
( O
27 O
) O
8 O
( O
10 O
) O
Hyperuricemia B-OSE_Labeled_AE
0 O
0 O
27 O
( O
33 O
) O
7 O
( O
8 O
) O
Serious O
Adverse O
Reactions O
Infections B-OSE_Labeled_AE
were O
the O
most O
common O
type O
of O
SAE O
reported O
in O
both O
studies O
with O
8 O
patients O
( O
8 O
% O
) O
in O
Study O
1 O
and O
26 O
patients O
( O
31 O
% O
) O
in O
Study O
2 O
experiencing O
a O
serious O
infection B-OSE_Labeled_AE
. O

Serious O
adverse O
reactions O
reported O
in O
> O
2 O
% O
of O
patients O
in O
Study O
1 O
were O
sepsis B-OSE_Labeled_AE
and O
pyrexia B-OSE_Labeled_AE
( O
3 O
% O
) O
. O

In O
Study O
2 O
, O
serious O
adverse O
reactions O
in O
> O
2 O
% O
of O
patients O
were O
fatigue B-OSE_Labeled_AE
( O
7 O
% O
) O
, O
supraventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
central B-OSE_Labeled_AE
line I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
hypotension B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
( O
5 O
% O
) O
, O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
catheter B-OSE_Labeled_AE
related I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
and O
dyspnea B-OSE_Labeled_AE
( O
4 O
% O
) O
. O

Most O
deaths B-NonOSE_AE
were O
due O
to O
disease O
progression O
. O

In O
Study O
1 O
, O
there O
were O
two O
deaths B-NonOSE_AE
due O
to O
cardiopulmonary B-NonOSE_AE
failure I-NonOSE_AE
and O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
. O

In O
Study O
2 O
, O
there O
were O
six O
deaths B-NonOSE_AE
due O
to O
infection B-NonOSE_AE
( O
4 O
) O
, O
myocardial B-NonOSE_AE
ischemia I-NonOSE_AE
, O
and O
acute B-NonOSE_AE
respiratory I-NonOSE_AE
distress I-NonOSE_AE
syndrome I-NonOSE_AE
. O

Discontinuations O
Discontinuation O
due O
to O
an O
adverse O
event O
occurred O
in O
21 O
% O
of O
patients O
in O
Study O
1 O
and O
11 O
% O
in O
Study O
2 O
. O

Discontinuations O
occurring O
in O
at O
least O
2 O
% O
of O
patients O
in O
either O
study O
included O
infection B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
, O
and O
hypomagnesemia B-OSE_Labeled_AE
. O

Peripheral O
T-Cell O
Lymphoma O
The O
safety O
of O
ISTODAX O
was O
evaluated O
in O
178 O
patients O
with O
PTCL B-Not_AE_Candidate
in O
a O
sponsor-conducted O
pivotal O
study O
( O
Study O
3 O
) O
and O
a O
secondary O
NCI-sponsored O
study O
( O
Study O
4 O
) O
in O
which O
patients O
received O
a O
starting O
dose O
of O
14 O
mg/m O
2 O
. O

The O
mean O
duration O
of O
treatment O
and O
number O
of O
cycles O
were O
5.6 O
months O
and O
6 O
cycles O
in O
Study O
3 O
and O
9.6 O
months O
and O
8 O
cycles O
in O
Study O
4 O
. O

Common O
Adverse O
Reactions O
Table O
2 O
summarizes O
the O
most O
frequent O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
regardless O
of O
causality O
, O
using O
the O
NCI-CTCAE O
, O
Version O
3.0 O
. O

The O
AE O
data O
are O
presented O
separately O
for O
Study O
3 O
and O
Study O
4 O
. O

Laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
commonly O
reported O
( O
> O
= O
10 O
% O
) O
as O
adverse O
reactions O
are O
included O
in O
Table O
2 O
. O

Table O
2 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
with O
PTCL O
in O
Study O
3 O
and O
Corresponding O
Incidence O
in O
Study O
4 O
( O
N=178 O
) O
Adverse O
Reactions O
n O
( O
% O
) O
Study O
3 O
( O
N=131 O
) O
Study O
4 O
( O
N=47 O
) O
All O
grades O
Grade O
3 O
or O
4 O
All O
grades O
Grade O
3 O
or O
4 O
Any O
adverse O
reactions O
128 O
( O
97 O
) O
88 O
( O
67 O
) O
47 O
( O
100 O
) O
40 O
( O
85 O
) O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
77 O
( O
59 O
) O
3 O
( O
2 O
) O
35 O
( O
75 O
) O
3 O
( O
6 O
) O
Vomiting B-OSE_Labeled_AE
51 O
( O
39 O
) O
6 O
( O
5 O
) O
19 O
( O
40 O
) O
4 O
( O
9 O
) O
Diarrhea B-OSE_Labeled_AE
47 O
( O
36 O
) O
3 O
( O
2 O
) O
17 O
( O
36 O
) O
1 O
( O
2 O
) O
Constipation B-OSE_Labeled_AE
39 O
( O
30 O
) O
1 O
( O
< O
1 O
) O
19 O
( O
40 O
) O
1 O
( O
2 O
) O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
18 O
( O
14 O
) O
3 O
( O
2 O
) O
6 O
( O
13 O
) O
1 O
( O
2 O
) O
Stomatitis B-OSE_Labeled_AE
14 O
( O
11 O
) O
0 O
3 O
( O
6 O
) O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
/ O
Fatigue B-OSE_Labeled_AE
72 O
( O
55 O
) O
11 O
( O
8 O
) O
36 O
( O
77 O
) O
9 O
( O
19 O
) O
Pyrexia B-OSE_Labeled_AE
46 O
( O
35 O
) O
8 O
( O
6 O
) O
22 O
( O
47 O
) O
8 O
( O
17 O
) O
Chills B-OSE_Labeled_AE
14 O
( O
11 O
) O
1 O
( O
< O
1 O
) O
8 O
( O
17 O
) O
0 O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
13 O
( O
10 O
) O
1 O
( O
< O
1 O
) O
3 O
( O
6 O
) O
0 O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Thrombocytopenia B-OSE_Labeled_AE
53 O
( O
41 O
) O
32 O
( O
24 O
) O
34 O
( O
72 O
) O
17 O
( O
36 O
) O
Neutropenia B-OSE_Labeled_AE
39 O
( O
30 O
) O
26 O
( O
20 O
) O
31 O
( O
66 O
) O
22 O
( O
47 O
) O
Anemia B-OSE_Labeled_AE
33 O
( O
25 O
) O
14 O
( O
11 O
) O
29 O
( O
62 O
) O
13 O
( O
28 O
) O
Leukopenia B-OSE_Labeled_AE
16 O
( O
12 O
) O
8 O
( O
6 O
) O
26 O
( O
55 O
) O
21 O
( O
45 O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
37 O
( O
28 O
) O
2 O
( O
2 O
) O
21 O
( O
45 O
) O
1 O
( O
2 O
) O
Hypokalemia B-OSE_Labeled_AE
14 O
( O
11 O
) O
3 O
( O
2 O
) O
8 O
( O
17 O
) O
1 O
( O
2 O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dysgeusia B-OSE_Labeled_AE
27 O
( O
21 O
) O
0 O
13 O
( O
28 O
) O
0 O
Headache B-OSE_Labeled_AE
19 O
( O
15 O
) O
0 O
16 O
( O
34 O
) O
1 O
( O
2 O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
23 O
( O
18 O
) O
0 O
10 O
( O
21 O
) O
0 O
Dyspnea B-OSE_Labeled_AE
17 O
( O
13 O
) O
3 O
( O
2 O
) O
10 O
( O
21 O
) O
2 O
( O
4 O
) O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
14 O
( O
11 O
) O
0 O
7 O
( O
15 O
) O
0 O
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
Tachycardia B-OSE_Labeled_AE
13 O
( O
10 O
) O
0 O
0 O
0 O
Serious O
Adverse O
Reactions O
Infections B-OSE_Labeled_AE
were O
the O
most O
common O
type O
of O
SAE O
reported O
. O

In O
Study O
3 O
, O
26 O
patients O
( O
20 O
% O
) O
experienced O
a O
serious O
infection B-OSE_Labeled_AE
, O
including O
6 O
patients O
( O
5 O
% O
) O
with O
serious O
treatment-related O
infections B-OSE_Labeled_AE
. O

In O
Study O
4 O
, O
11 O
patients O
( O
23 O
% O
) O
experienced O
a O
serious O
infection B-OSE_Labeled_AE
, O
including O
8 O
patients O
( O
17 O
% O
) O
with O
serious O
treatment-related O
infections B-OSE_Labeled_AE
. O

Serious O
adverse O
reactions O
reported O
in O
> O
= O
2 O
% O
of O
patients O
in O
Study O
3 O
were O
pyrexia B-OSE_Labeled_AE
( O
8 O
% O
) O
, O
pneumonia B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
( O
5 O
% O
) O
, O
cellulitis B-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
( O
4 O
% O
) O
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
3 O
% O
) O
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
and O
dehydration B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

In O
Study O
4 O
, O
serious O
adverse O
reactions O
in O
> O
= O
2 O
patients O
were O
pyrexia B-OSE_Labeled_AE
( O
17 O
% O
) O
, O
aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
( O
13 O
% O
) O
, O
anemia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
11 O
% O
) O
, O
infection B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
( O
9 O
% O
) O
, O
lymphopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
hyperbilirubinemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hypoxia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
hypersensitivity B-OSE_Labeled_AE
, O
catheter B-OSE_Labeled_AE
related I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypoalbuminemia B-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
pneumonitis B-OSE_Labeled_AE
, O
packed O
red O
blood O
cell O
transfusion O
, O
and O
platelet O
transfusion O
( O
4 O
% O
) O
. O

Reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
has O
occurred O
in O
1 O
% O
of O
patients O
with O
PTCL B-Not_AE_Candidate
patients O
in O
clinical O
trials O
in O
Western O
population O
enrolled O
in O
Study O
3 O
and O
Study O
4 O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Deaths B-NonOSE_AE
due O
to O
all O
causes O
within O
30 O
days O
of O
the O
last O
dose O
of O
ISTODAX O
occurred O
in O
7 O
% O
of O
patients O
in O
Study O
3 O
and O
17 O
% O
of O
patients O
in O
Study O
4 O
. O

In O
Study O
3 O
, O
there O
were O
5 O
deaths B-NonOSE_AE
unrelated O
to O
disease O
progression O
that O
were O
due O
to O
infections B-NonOSE_AE
, O
including O
multi B-NonOSE_AE
- I-NonOSE_AE
organ I-NonOSE_AE
failure I-NonOSE_AE
/ O
sepsis B-NonOSE_AE
, O
pneumonia B-NonOSE_AE
, O
septic B-NonOSE_AE
shock I-NonOSE_AE
, O
candida B-NonOSE_AE
sepsis I-NonOSE_AE
, O
and O
sepsis B-OSE_Labeled_AE
/ O
cardiogenic B-NonOSE_AE
shock I-NonOSE_AE
. O

In O
Study O
4 O
, O
there O
were O
3 O
deaths B-NonOSE_AE
unrelated O
to O
disease O
progression O
that O
were O
due O
to O
sepsis B-OSE_Labeled_AE
, O
aspartate B-NonOSE_AE
aminotransferase I-NonOSE_AE
elevation I-NonOSE_AE
in O
the O
setting O
of O
Epstein B-NonOSE_AE
Barr I-NonOSE_AE
virus I-NonOSE_AE
reactivation I-NonOSE_AE
, O
and O
death B-NonOSE_AE
of O
unknown O
cause O
. O

Discontinuations O
Discontinuation O
due O
to O
an O
adverse O
event O
occurred O
in O
19 O
% O
of O
patients O
in O
Study O
3 O
and O
in O
28 O
% O
of O
patients O
in O
Study O
4 O
. O

In O
Study O
3 O
, O
thrombocytopenia B-OSE_Labeled_AE
and O
pneumonia B-OSE_Labeled_AE
were O
the O
only O
events O
leading O
to O
treatment O
discontinuation O
in O
at O
least O
2 O
% O
of O
patients O
. O

In O
Study O
4 O
, O
events O
leading O
to O
treatment O
discontinuation O
in O
> O
= O
2 O
patients O
were O
thrombocytopenia B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
anemia B-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
and O
alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
4 O
% O
) O
. O

6.2 O
Postmarketing O
Experience O
No O
additional O
safety O
signals O
have O
been O
observed O
from O
postmarketing O
experience O
. O

